UroGen has issued $4m in ordinary shares to IconOVir. Credit: MacroEcon/Shutterstock. UroGen Pharma has broadened its oncology pipeline by acquiring IconOVir Bio’s assets related to
The partnership is set to discover and optimise small molecule compounds required for the targets. Credit: totojang1977/Shutterstock. Incyte and Genesis Therapeutics have entered a strategic
CSL Behring’s Andembry is the first fully human monoclonal antibody in the country that targets activated Factor XII. Credit: © 2023 CSL, All Rights Reserved.
A pivotal Phase III trial is being conducted by the company to investigate the therapy. Credit: shisu_ka via Shutterstock. US-based X4 Pharmaceuticals has entered an
The company holds several patents for the composition and use of BCG combined with Anktiva in bladder cancer treatment. Credit: SaiArLawKa2/Shutterstock. ImmunityBio has gained US
The therapy is being developed for HER2-mutant advanced NSCLC. Credit: Jo Panuwat D/Shutterstock. The US Food and Drug Administration (FDA) has granted priority review to
Vibativ is tailored to combat ventilator-associated and hospital-acquired pneumonia caused by Gram-positive bacteria. Credit: mi_viri/Shutterstock. Cumberland Pharmaceuticals’ antibiotic Vibativ (telavancin) injection has gained approval from
Zorevunersen is intended for treating Dravet syndrome. Credit: Maks_lab/Shutterstock. Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat
Bar-Zohar’s tenure at the company began in 2020 as development global head. Credit: © 2017 – 2025 Merck KGaA, Darmstadt, Germany and/or its affiliates. All
In the EU, MSD’s Welireg is the first and only systemic therapy for treating VHL disease-associated tumours. Credit: Tada Images/Shutterstock. The European Commission (EC) has